Type 1 Diabetes Extension Study (NCT02734277)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
Who can join: Review the eligibility criteria below.
Location: UCSF School of Medicine — San Francisco, California
Age range: 8 Years to 35 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- UCSF School of Medicine — San Francisco, California
- Stanford University — Stanford, California
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes — Aurora, Colorado
- Yale University — New Haven, Connecticut
- Emory University — Atlanta, Georgia
- Indiana University Riley Hospital for Children — Indianapolis, Indiana
- University of Iowa Health Care Division of Pediatric Endocrinology — Iowa City, Iowa
- Joslin Diabetes Center — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- Children's Mercy Hospital — Kansas City, Missouri
- Sanford Research — Sioux Falls, South Dakota
- Benaroya Research Institute — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (415) 476-5984
Email: rebecca.wesch@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 1 Diabetes Mellitus
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) — Chicago, Illinois
- Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes — Orange, California
- A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation — Chicago, Illinois
- Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus — Walnut Creek, California
- Triple Therapy in T1DM — Williamsville, New York
- Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) — Toronto, British Columbia
Explore by condition: All Type 1 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.